The health and quality of life of Thalidomide survivors as they age - Evidence from a UK survey
In the late 1950s and early 1960s the drug Thalidomide was marketed across the world as a non-addictive tranquilizer. Despite being given to pregnant women as a safe treatment for morning sickness, Thalidomide caused serious damage to the unborn child. Much has been written about the drug and the bi...
Gespeichert in:
| Veröffentlicht in: | PloS one 2019-01, Vol.14 (1), p.e0210222-e0210222 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0210222 |
|---|---|
| container_issue | 1 |
| container_start_page | e0210222 |
| container_title | PloS one |
| container_volume | 14 |
| creator | Newbronner, Elizabeth Glendinning, Caroline Atkin, Karl Wadman, Ruth |
| description | In the late 1950s and early 1960s the drug Thalidomide was marketed across the world as a non-addictive tranquilizer. Despite being given to pregnant women as a safe treatment for morning sickness, Thalidomide caused serious damage to the unborn child. Much has been written about the drug and the birth defects it caused but evidence about the health of Thalidomide survivors as they age is limited.
The aim of this study was to: explore the health and wellbeing UK Thalidomide survivors; document the health problems experienced by them as they reach their mid-50s; and examine the impacts on their health-related quality of life and employment.
A health and wellbeing survey of 351 UK Thalidomide survivors, which gathered information about home and employment circumstances, recent health problems, and health related quality of life (using SF12 Health Survey). Overall analysis focused on descriptive statistics; the association between respondents' health related quality of life and original impairment was examined using Pearson Correlation; and a three step Hierarchical Regression was used to explore the influence of five factors which narrative responses suggested might be important.
As Thalidomide survivors reach their mid-50's they are experiencing a wide range of secondary health problems, in particular musculoskeletal problems, and depression and anxiety, with multimorbidity a growing issue. These health problems are having a negative impact on their employment (two fifths are unable to work) and their physical health related quality of life, which is significantly poorer than the general population.
Having lived relatively independent lives, many Thalidomide survivors are now having to adjust to growing disability. The study provides further evidence of the accumulative impact of disability over peoples' lifetimes and highlights the value of a life course perspective in understanding the complex experience of growing older with a disability. |
| doi_str_mv | 10.1371/journal.pone.0210222 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2167793104</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A569840696</galeid><doaj_id>oai_doaj_org_article_f1ae27daa6c2452bbabfe9c48a3e9b4e</doaj_id><sourcerecordid>A569840696</sourcerecordid><originalsourceid>FETCH-LOGICAL-c679t-99bf7f01ddf3d3478538479a7eede21353505b3163870c9fc9647c121ea462ee3</originalsourceid><addsrcrecordid>eNqNkl1v0zAUhiMEYmPwDxBYQkJw0eKv2PUN0jQNqJg0CTpurRPnuM2Uxp2dVPTfk6zZ1CIuuDqWz3Pe86E3y14zOmVCs0-3oYsN1NNNaHBKOaOc8yfZKTOCTxSn4unB-yR7kdItpbmYKfU8OxFU5ZQxdprZxQrJCqFuVwSaktx1UFftjgRP6srjEBer_qsM66pEkrq4rbYhJgKJtCvcEVgimZDLbZ9tHBIfw5oAufl-j-LuZfbMQ53w1RjPspsvl4uLb5Or66_zi_OriVPatBNjCq89ZWXpRSmknvWTSm1AI5bImchFTvNCMCVmmjrjnVFSO8YZglQcUZxlb_e6mzokO94mWc6U1kYwKntivifKALd2E6s1xJ0NUNn7jxCXFmJbuRqtZ4BclwDKcZnzooDCo3FyBgJNIYdun8duXbHG0mHTRqiPRI8zTbWyy7C1SghpctELfBgFYrjrMLV2XSWHdQ0Nhm6YWxtJRc5Vj777C_33diO1hH6BqvGh7-sGUXueKzOTVJlB6-MR5ULT4u92CV1Kdv7zx_-z17-O2fcH7N5OKdRdW4UmHYNyD7oYUoroH2_GqB1s_bCcHWxtR1v3ZW8O7_1Y9OBj8Qc8YvHT</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2167793104</pqid></control><display><type>article</type><title>The health and quality of life of Thalidomide survivors as they age - Evidence from a UK survey</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Newbronner, Elizabeth ; Glendinning, Caroline ; Atkin, Karl ; Wadman, Ruth</creator><creatorcontrib>Newbronner, Elizabeth ; Glendinning, Caroline ; Atkin, Karl ; Wadman, Ruth</creatorcontrib><description>In the late 1950s and early 1960s the drug Thalidomide was marketed across the world as a non-addictive tranquilizer. Despite being given to pregnant women as a safe treatment for morning sickness, Thalidomide caused serious damage to the unborn child. Much has been written about the drug and the birth defects it caused but evidence about the health of Thalidomide survivors as they age is limited.
The aim of this study was to: explore the health and wellbeing UK Thalidomide survivors; document the health problems experienced by them as they reach their mid-50s; and examine the impacts on their health-related quality of life and employment.
A health and wellbeing survey of 351 UK Thalidomide survivors, which gathered information about home and employment circumstances, recent health problems, and health related quality of life (using SF12 Health Survey). Overall analysis focused on descriptive statistics; the association between respondents' health related quality of life and original impairment was examined using Pearson Correlation; and a three step Hierarchical Regression was used to explore the influence of five factors which narrative responses suggested might be important.
As Thalidomide survivors reach their mid-50's they are experiencing a wide range of secondary health problems, in particular musculoskeletal problems, and depression and anxiety, with multimorbidity a growing issue. These health problems are having a negative impact on their employment (two fifths are unable to work) and their physical health related quality of life, which is significantly poorer than the general population.
Having lived relatively independent lives, many Thalidomide survivors are now having to adjust to growing disability. The study provides further evidence of the accumulative impact of disability over peoples' lifetimes and highlights the value of a life course perspective in understanding the complex experience of growing older with a disability.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0210222</identifier><identifier>PMID: 30650111</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Aging ; Aging - drug effects ; Aging - pathology ; Anxiety ; Anxiety - chemically induced ; Anxiety - epidemiology ; Biology and Life Sciences ; Birth defects ; Brexit ; Censuses ; Congenital defects ; Congenital diseases ; Depression - chemically induced ; Depression - epidemiology ; Disability ; Employment ; Female ; Health ; Health aspects ; Health problems ; Health sciences ; Health services ; Humans ; Hypnotics and Sedatives ; Male ; Medicine and Health Sciences ; Mental depression ; Mental health ; Middle age ; Middle Aged ; Morning Sickness - drug therapy ; Morning Sickness - epidemiology ; Morning Sickness - physiopathology ; Pregnancy ; Pregnant women ; Quality of Life ; Regression analysis ; Research and Analysis Methods ; Social Sciences ; Statistical analysis ; Surveys ; Surveys and Questionnaires ; Survivors ; Thalidomide ; Thalidomide - adverse effects ; Well being ; Young Adult</subject><ispartof>PloS one, 2019-01, Vol.14 (1), p.e0210222-e0210222</ispartof><rights>COPYRIGHT 2019 Public Library of Science</rights><rights>2019 Newbronner et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 Newbronner et al 2019 Newbronner et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c679t-99bf7f01ddf3d3478538479a7eede21353505b3163870c9fc9647c121ea462ee3</citedby><cites>FETCH-LOGICAL-c679t-99bf7f01ddf3d3478538479a7eede21353505b3163870c9fc9647c121ea462ee3</cites><orcidid>0000-0003-2366-9981</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334953/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334953/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79569,79570</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30650111$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Newbronner, Elizabeth</creatorcontrib><creatorcontrib>Glendinning, Caroline</creatorcontrib><creatorcontrib>Atkin, Karl</creatorcontrib><creatorcontrib>Wadman, Ruth</creatorcontrib><title>The health and quality of life of Thalidomide survivors as they age - Evidence from a UK survey</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>In the late 1950s and early 1960s the drug Thalidomide was marketed across the world as a non-addictive tranquilizer. Despite being given to pregnant women as a safe treatment for morning sickness, Thalidomide caused serious damage to the unborn child. Much has been written about the drug and the birth defects it caused but evidence about the health of Thalidomide survivors as they age is limited.
The aim of this study was to: explore the health and wellbeing UK Thalidomide survivors; document the health problems experienced by them as they reach their mid-50s; and examine the impacts on their health-related quality of life and employment.
A health and wellbeing survey of 351 UK Thalidomide survivors, which gathered information about home and employment circumstances, recent health problems, and health related quality of life (using SF12 Health Survey). Overall analysis focused on descriptive statistics; the association between respondents' health related quality of life and original impairment was examined using Pearson Correlation; and a three step Hierarchical Regression was used to explore the influence of five factors which narrative responses suggested might be important.
As Thalidomide survivors reach their mid-50's they are experiencing a wide range of secondary health problems, in particular musculoskeletal problems, and depression and anxiety, with multimorbidity a growing issue. These health problems are having a negative impact on their employment (two fifths are unable to work) and their physical health related quality of life, which is significantly poorer than the general population.
Having lived relatively independent lives, many Thalidomide survivors are now having to adjust to growing disability. The study provides further evidence of the accumulative impact of disability over peoples' lifetimes and highlights the value of a life course perspective in understanding the complex experience of growing older with a disability.</description><subject>Adult</subject><subject>Aging</subject><subject>Aging - drug effects</subject><subject>Aging - pathology</subject><subject>Anxiety</subject><subject>Anxiety - chemically induced</subject><subject>Anxiety - epidemiology</subject><subject>Biology and Life Sciences</subject><subject>Birth defects</subject><subject>Brexit</subject><subject>Censuses</subject><subject>Congenital defects</subject><subject>Congenital diseases</subject><subject>Depression - chemically induced</subject><subject>Depression - epidemiology</subject><subject>Disability</subject><subject>Employment</subject><subject>Female</subject><subject>Health</subject><subject>Health aspects</subject><subject>Health problems</subject><subject>Health sciences</subject><subject>Health services</subject><subject>Humans</subject><subject>Hypnotics and Sedatives</subject><subject>Male</subject><subject>Medicine and Health Sciences</subject><subject>Mental depression</subject><subject>Mental health</subject><subject>Middle age</subject><subject>Middle Aged</subject><subject>Morning Sickness - drug therapy</subject><subject>Morning Sickness - epidemiology</subject><subject>Morning Sickness - physiopathology</subject><subject>Pregnancy</subject><subject>Pregnant women</subject><subject>Quality of Life</subject><subject>Regression analysis</subject><subject>Research and Analysis Methods</subject><subject>Social Sciences</subject><subject>Statistical analysis</subject><subject>Surveys</subject><subject>Surveys and Questionnaires</subject><subject>Survivors</subject><subject>Thalidomide</subject><subject>Thalidomide - adverse effects</subject><subject>Well being</subject><subject>Young Adult</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNkl1v0zAUhiMEYmPwDxBYQkJw0eKv2PUN0jQNqJg0CTpurRPnuM2Uxp2dVPTfk6zZ1CIuuDqWz3Pe86E3y14zOmVCs0-3oYsN1NNNaHBKOaOc8yfZKTOCTxSn4unB-yR7kdItpbmYKfU8OxFU5ZQxdprZxQrJCqFuVwSaktx1UFftjgRP6srjEBer_qsM66pEkrq4rbYhJgKJtCvcEVgimZDLbZ9tHBIfw5oAufl-j-LuZfbMQ53w1RjPspsvl4uLb5Or66_zi_OriVPatBNjCq89ZWXpRSmknvWTSm1AI5bImchFTvNCMCVmmjrjnVFSO8YZglQcUZxlb_e6mzokO94mWc6U1kYwKntivifKALd2E6s1xJ0NUNn7jxCXFmJbuRqtZ4BclwDKcZnzooDCo3FyBgJNIYdun8duXbHG0mHTRqiPRI8zTbWyy7C1SghpctELfBgFYrjrMLV2XSWHdQ0Nhm6YWxtJRc5Vj777C_33diO1hH6BqvGh7-sGUXueKzOTVJlB6-MR5ULT4u92CV1Kdv7zx_-z17-O2fcH7N5OKdRdW4UmHYNyD7oYUoroH2_GqB1s_bCcHWxtR1v3ZW8O7_1Y9OBj8Qc8YvHT</recordid><startdate>20190116</startdate><enddate>20190116</enddate><creator>Newbronner, Elizabeth</creator><creator>Glendinning, Caroline</creator><creator>Atkin, Karl</creator><creator>Wadman, Ruth</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2366-9981</orcidid></search><sort><creationdate>20190116</creationdate><title>The health and quality of life of Thalidomide survivors as they age - Evidence from a UK survey</title><author>Newbronner, Elizabeth ; Glendinning, Caroline ; Atkin, Karl ; Wadman, Ruth</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c679t-99bf7f01ddf3d3478538479a7eede21353505b3163870c9fc9647c121ea462ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aging</topic><topic>Aging - drug effects</topic><topic>Aging - pathology</topic><topic>Anxiety</topic><topic>Anxiety - chemically induced</topic><topic>Anxiety - epidemiology</topic><topic>Biology and Life Sciences</topic><topic>Birth defects</topic><topic>Brexit</topic><topic>Censuses</topic><topic>Congenital defects</topic><topic>Congenital diseases</topic><topic>Depression - chemically induced</topic><topic>Depression - epidemiology</topic><topic>Disability</topic><topic>Employment</topic><topic>Female</topic><topic>Health</topic><topic>Health aspects</topic><topic>Health problems</topic><topic>Health sciences</topic><topic>Health services</topic><topic>Humans</topic><topic>Hypnotics and Sedatives</topic><topic>Male</topic><topic>Medicine and Health Sciences</topic><topic>Mental depression</topic><topic>Mental health</topic><topic>Middle age</topic><topic>Middle Aged</topic><topic>Morning Sickness - drug therapy</topic><topic>Morning Sickness - epidemiology</topic><topic>Morning Sickness - physiopathology</topic><topic>Pregnancy</topic><topic>Pregnant women</topic><topic>Quality of Life</topic><topic>Regression analysis</topic><topic>Research and Analysis Methods</topic><topic>Social Sciences</topic><topic>Statistical analysis</topic><topic>Surveys</topic><topic>Surveys and Questionnaires</topic><topic>Survivors</topic><topic>Thalidomide</topic><topic>Thalidomide - adverse effects</topic><topic>Well being</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Newbronner, Elizabeth</creatorcontrib><creatorcontrib>Glendinning, Caroline</creatorcontrib><creatorcontrib>Atkin, Karl</creatorcontrib><creatorcontrib>Wadman, Ruth</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Newbronner, Elizabeth</au><au>Glendinning, Caroline</au><au>Atkin, Karl</au><au>Wadman, Ruth</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The health and quality of life of Thalidomide survivors as they age - Evidence from a UK survey</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2019-01-16</date><risdate>2019</risdate><volume>14</volume><issue>1</issue><spage>e0210222</spage><epage>e0210222</epage><pages>e0210222-e0210222</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>In the late 1950s and early 1960s the drug Thalidomide was marketed across the world as a non-addictive tranquilizer. Despite being given to pregnant women as a safe treatment for morning sickness, Thalidomide caused serious damage to the unborn child. Much has been written about the drug and the birth defects it caused but evidence about the health of Thalidomide survivors as they age is limited.
The aim of this study was to: explore the health and wellbeing UK Thalidomide survivors; document the health problems experienced by them as they reach their mid-50s; and examine the impacts on their health-related quality of life and employment.
A health and wellbeing survey of 351 UK Thalidomide survivors, which gathered information about home and employment circumstances, recent health problems, and health related quality of life (using SF12 Health Survey). Overall analysis focused on descriptive statistics; the association between respondents' health related quality of life and original impairment was examined using Pearson Correlation; and a three step Hierarchical Regression was used to explore the influence of five factors which narrative responses suggested might be important.
As Thalidomide survivors reach their mid-50's they are experiencing a wide range of secondary health problems, in particular musculoskeletal problems, and depression and anxiety, with multimorbidity a growing issue. These health problems are having a negative impact on their employment (two fifths are unable to work) and their physical health related quality of life, which is significantly poorer than the general population.
Having lived relatively independent lives, many Thalidomide survivors are now having to adjust to growing disability. The study provides further evidence of the accumulative impact of disability over peoples' lifetimes and highlights the value of a life course perspective in understanding the complex experience of growing older with a disability.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>30650111</pmid><doi>10.1371/journal.pone.0210222</doi><tpages>e0210222</tpages><orcidid>https://orcid.org/0000-0003-2366-9981</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2019-01, Vol.14 (1), p.e0210222-e0210222 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2167793104 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Adult Aging Aging - drug effects Aging - pathology Anxiety Anxiety - chemically induced Anxiety - epidemiology Biology and Life Sciences Birth defects Brexit Censuses Congenital defects Congenital diseases Depression - chemically induced Depression - epidemiology Disability Employment Female Health Health aspects Health problems Health sciences Health services Humans Hypnotics and Sedatives Male Medicine and Health Sciences Mental depression Mental health Middle age Middle Aged Morning Sickness - drug therapy Morning Sickness - epidemiology Morning Sickness - physiopathology Pregnancy Pregnant women Quality of Life Regression analysis Research and Analysis Methods Social Sciences Statistical analysis Surveys Surveys and Questionnaires Survivors Thalidomide Thalidomide - adverse effects Well being Young Adult |
| title | The health and quality of life of Thalidomide survivors as they age - Evidence from a UK survey |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T16%3A06%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20health%20and%20quality%20of%20life%20of%20Thalidomide%20survivors%20as%20they%20age%20-%20Evidence%20from%20a%20UK%20survey&rft.jtitle=PloS%20one&rft.au=Newbronner,%20Elizabeth&rft.date=2019-01-16&rft.volume=14&rft.issue=1&rft.spage=e0210222&rft.epage=e0210222&rft.pages=e0210222-e0210222&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0210222&rft_dat=%3Cgale_plos_%3EA569840696%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2167793104&rft_id=info:pmid/30650111&rft_galeid=A569840696&rft_doaj_id=oai_doaj_org_article_f1ae27daa6c2452bbabfe9c48a3e9b4e&rfr_iscdi=true |